Exact Sciences (EXAS) Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Exact Sciences (EXAS) Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45

UBS Downgrades Exact Sciences (EXAS) to Neutral

October 29, 2020 6:11 AM EDT

UBS analyst Dan Brennan downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral with a price target of $140.00 (from $125.00).

The analyst comments "We like the Thrive Deal on many levels, though timelines are lengthy & visibility limited. With COVID-19 pressuring the base business, plus... More